PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI

使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成

• 批准号: 7951676
• 负责人: GARETH PARRY
• 金额: $ 0.11万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951676
• 关键词: Antibodies; Antibody Formation; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Development; Effectiveness; Funding; Grant; Institution; Interferon-beta; Methylprednisolone; Patients; Relapsing-Remitting Multiple Sclerosis; Research; Research Personnel; Resources; Source; Steroids; Therapeutic Effect; United States National Institutes of Health; avonex; improved; neutralizing antibody; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Interferon-beta (IFN-beta; e.g., Rebif) is the most frequently used first-line treatment for relapsing-remitting multiple sclerosis (RRMS). Several studies have shown that the use of IFN-beta produces neutralizing antibodies (NAbs) in a significant proportion of MS patients, which are thought to decrease the bio-availability of IFN-beta and reduce its therapeutic effects. This study will examine whether the addition of steroids (methylprednisolone; MP) to the treatment regime will prevent or decrease the development of antibodies, thus improving the effectiveness of Rebif.

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 干扰素-β（IFN-β;例如，Rebif）是复发缓解型多发性硬化症（RRMS）最常用的一线治疗药物。几项研究表明，IFN-β的使用在相当大比例的MS患者中产生中和抗体（NAb），这被认为会降低IFN-β的生物利用度并降低其治疗效果。这项研究将检查在治疗方案中加入类固醇（甲基强的松龙; MP）是否会预防或减少抗体的产生，从而提高Rebif的有效性。